Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting

CAMBRIDGE, Mass.--()--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, announced that a late breaking abstract describing results from the ACE-083 Phase 1 clinical trial has been selected for an oral plenary presentation in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia, and Muscle Wasting. The conference will take place in Paris, France, December 4-6, 2015.

ACE-083 has been designed to increase muscle mass and strength selectively in the muscles into which the drug is administered. Acceleron is developing ACE-083 for diseases such as facioscapulohumeral and certain other forms of muscular dystrophy in which improved muscle strength in a specific set of muscles may provide a clinical benefit.

 

Oral Presentation

Date:   Saturday, December 5
Title:

A Phase 1 Dose Escalation Study of ACE-083 in Healthy Volunteers: Preliminary Results for a Locally Acting Muscle Therapeutic (Abstract #1-72)

Session: 55. Clinical science track: Late breaking clinical trials & trial updates
Time: 4:30 - 6:30 PM CET
Location: Novotel Paris Tour Eiffel, Hall A
 

Poster Presentation

Date: Sunday, December 6
Title:

A Phase 1 Dose Escalation Study of ACE-083 in Healthy Volunteers: Preliminary Results for a Locally Acting Muscle Therapeutic (Abstract #1-72)

Session: 16. Muscle wasting, sarcopenia, myopenia VI
Time: 9:35 - 10:25 AM CET
Location: Novotel Paris Tour Eiffel, Poster Area
 

The clinical presentation and poster will be available on Acceleron’s website (www.acceleronpharma.com) under the “Publications” tab when presented at the conference.

About ACE-083

ACE-083 is a therapeutic candidate that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-β) superfamily involved in the regulation of muscle mass and strength. ACE-083 has been designed to increase muscle mass and strength selectively in the muscles into which the drug is administered. Acceleron is developing ACE-083 for diseases in which improved muscle strength in a specific set of muscles may provide a clinical benefit, such as facioscapulohumeral and certain other forms of muscular dystrophy. ACE-083 is currently in a phase 1 clinical trial in healthy volunteers. For additional information on this clinical trial, please visit www.clinicaltrials.gov, identifier NCT02257489.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical therapeutic candidates with novel mechanisms of action. These therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

Contacts

Acceleron Pharma Inc.
Todd James, 617-649-9393
Senior Director, Corporate Communications
or
Media:
BMC Communications LLC
Brad Miles, 646-513-3125

Recent Stories

RSS feed for Acceleron Pharma

Acceleron Pharma